StartUPDATES: New developments from healthcare startups

Read about new developments and milestones in the journey of healthcare startups from Truvian Sciences, NeuroFlow and more.

Vector illustration - Startup

Truvian Sciences receives FDA Emergency Use Authorization for Easy Check COVID-19 IgM/IgG Test: Rigorously and independently tested and validated, Easy Check exceeds current testing requirements for the detection of IgM/IgG antibodies to SARS-CoV-2.

Truvian Sciences (Truvian), a healthcare company at the intersection of diagnostics and consumer technology, announced that the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the company’s Easy Check COVID-19 IgM/IgG™ antibody test. Truvian’s Easy Check test is being produced at mass scale at a US based manufacturing facility and will be available to healthcare practitioners immediately.

The test, which has been rigorously tested and validated by leading healthcare professionals and scientific experts at University of California San Diego (UCSD) and the University of Chicago, exceeds the current EUA requirements for current COVID-19 antibody tests by delivering a sensitivity rate of 98.44 percent and a specificity of 98.9 percent. Additionally, the cross-reactivity evaluation determined no cross-reactivity (0 percent) with HIV, Influenza A and B and several coronavirus strains.

“Truvian’s Easy Check performed exceptionally well, with a robust sample set, in both our own studies, as well as the studies conducted by independent laboratories,” said Jeff Hawkins, President and Chief Executive Officer, Truvian Sciences. “With its consistent reproducibility, we are confident our testing solution, backed by the FDA’s EUA, will set a higher bar for COVID-19 antibody testing.”

NeuroFlow has added two key advisers to the team. (Ret.) USAF Brig. General Carl Buhler and Pat Saxman, two military veterans with extensive networks and experience advocating for mental health causes, will support growth stage decisions for the company.

Nura Bio, a biopharma company created to discover and develop life-changing neuroprotective drugs, raised $73 million in a Series A round. The Column Group led the round as a syndicate together with Samsara BioCapital and Euclidean Capital. Click here to read more.

MedCity INVEST Digital Health will spotlight healthcare startups in a pitch competition across four tracks, including: Home Health, Chronic Disease Management/Value-Based Care, Tech to Boost Payer/Provider Efficiency, and Employee Benefits. Click here to learn more.

Picture: akindo, Getty Images